Literature DB >> 3867335

Microbial contamination of domiciliary nebuliser therapy equipment.

P D Jones, V Moritz, R J Pierce.   

Abstract

Fifty-two outpatients requiring domiciliary nebulised bronchodilator therapy were studied to determine the frequency and degree of contamination of nebuliser solutions and equipment. In 32 of the 52 patients (61%) nebuliser solutions and/or aerosols were contaminated. The degree of contamination was greater than that of ambient air in 90% of the contaminated aerosols. Diluent solutions were more frequently contaminated than salbutamol solutions (51% vs. 9%) and the organisms isolated from the solutions frequently correlated with those in aerosols. Gram-negative bacilli, particularly Pseudomonas species, were the most frequently isolated organisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3867335

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  5 in total

1.  Aerosolization of lipoplexes using AERx Pulmonary Delivery System.

Authors:  Deepa Deshpande; James Blanchard; Sudarshan Srinivasan; Dallas Fairbanks; Jun Fujimoto; Teiji Sawa; Jeanine Wiener-Kronish; Hans Schreier; Igor Gonda
Journal:  AAPS PharmSci       Date:  2002

2.  Bacterial contamination of home nebuliser.

Authors:  K L Barnes; R Clifford; S T Holgate; D Murphy; P Comber; E Bell
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-03

3.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Bacterial reservoirs in cystic fibrosis.

Authors:  C J Taylor; J McGaw; R Howden; B I Duerden; P S Baxter
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

5.  Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.

Authors:  G R Hutchinson; S Parker; J A Pryor; F Duncan-Skingle; P N Hoffman; M E Hodson; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.